AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Intensity Therapeutics Statistics
Share Statistics
Intensity Therapeutics has 15.10M shares outstanding. The number of shares has increased by 10.18% in one year.
Shares Outstanding | 15.10M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 9.68% |
Owned by Institutions (%) | n/a |
Shares Floating | 7.58M |
Failed to Deliver (FTD) Shares | 5.26K |
FTD / Avg. Volume | 17.13% |
Short Selling Information
The latest short interest is 44.28K, so 0.29% of the outstanding shares have been sold short.
Short Interest | 44.28K |
Short % of Shares Out | 0.29% |
Short % of Float | 0.58% |
Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -7.01 and the forward PE ratio is -2.87.
PE Ratio | -7.01 |
Forward PE | -2.87 |
PS Ratio | 0 |
Forward PS | 13.3 |
PB Ratio | 5.61 |
P/FCF Ratio | -10.25 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intensity Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.
Current Ratio | 3.91 |
Quick Ratio | 3.91 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -27.28 |
Financial Efficiency
Return on equity (ROE) is -0.8% and return on capital (ROIC) is -62.45%.
Return on Equity (ROE) | -0.8% |
Return on Assets (ROA) | -0.61% |
Return on Capital (ROIC) | -62.45% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.11M |
Employee Count | 5 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -52.86% in the last 52 weeks. The beta is 5.13, so Intensity Therapeutics 's price volatility has been higher than the market average.
Beta | 5.13 |
52-Week Price Change | -52.86% |
50-Day Moving Average | 2.54 |
200-Day Moving Average | 3.89 |
Relative Strength Index (RSI) | 63.2 |
Average Volume (20 Days) | 30.71K |
Income Statement
Revenue | n/a |
Gross Profit | -147.00K |
Operating Income | -8.32M |
Net Income | -10.54M |
EBITDA | -10.09M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.38 |
Balance Sheet
The company has 8.56M in cash and 158.00K in debt, giving a net cash position of 8.40M.
Cash & Cash Equivalents | 8.56M |
Total Debt | 158.00K |
Net Cash | 8.40M |
Retained Earnings | -50.52M |
Total Assets | 5.21M |
Working Capital | 1.47M |
Cash Flow
In the last 12 months, operating cash flow was -7.21M and capital expenditures 0, giving a free cash flow of -7.21M.
Operating Cash Flow | -7.21M |
Capital Expenditures | 0 |
Free Cash Flow | -7.21M |
FCF Per Share | -0.84 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
INTS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -52.27% |
FCF Yield | -18.07% |
Analyst Forecast
The average price target for INTS is $8.5, which is 222% higher than the current price. The consensus rating is "Buy".
Price Target | $8.5 |
Price Target Difference | 222% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -20.02 |
Piotroski F-Score | 2 |